Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-α2B

Journal of Endourology

Volumn 21, Issue 4, 2007, Pages 374-377

  Katz, Mark H ^a   Lee, Michael W ^a   Gupta, Mantu ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE;

AGED; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOSCOPY; ENDOSCOPIC BIOPSY; FEMALE; FOLLOW UP; HUMAN; KIDNEY PELVIS; MALE; MICTURITION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TUMOR VOLUME; URETER CATHETER; URETEROSCOPY; URINARY TRACT CARCINOMA;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CATHETERIZATION; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; URETERAL NEOPLASMS;

EID: 34248550444     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2007.9969     Document Type: Article

References (10)

1. Thalmann GN, Markwalder R, Walter B, Studer UE. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol 2002;168:1381-1385.
2. Elliott DS, Segura JW, Lightner D, Patterson DE, Blute ML. Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney. Urology 2001;58:174-178.
3. Nonomura N, Ono Y, Nozawa M, et al. Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol 2000;38:701-704; discussion 705.
4. Nishino Y, Yamamoto N, Komeda H, Takahashi Y, Deguchi T. Bacillus Calmette-Guerin instillation treatment for carcinoma in situ of the upper urinary tract. BJU Int 2000;85:799-801.
5. O'Donnell MA, Lilli K, Leopold C, National Bacillus Calmette-Guerin/ Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004;172:888-893.
6. Punnen SP, Chin JL, Jewett MA. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: Results with intravesical BCG and interferon combination therapy. Can J Urol 2003;10:1790-1795.
7. Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 1999;162:2399-2405.
8. Malmstrom PU. A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int 2002;89:681-686.
9. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001;166:1300-1304.
10. Yokogi H, Wada Y, Mizutani M, Igawa M, Ishibe T. Bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract. Br J Urol 1996;77:676-679.